References
- Swerdlow SH Campo E, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In Hasserjian RP, Gattermann N, Bennett JM, et al., editors. Refractory anaemia with ring sideroblasts. 4th edition. Lyon: IARC; 2008. pp 96–97.
- Gerds AT. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. Curr Hematol Malig Rep 2014;9: 400–406.
- Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008;22:1308–1319.
- Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008;93:34–40.
- Broseus J, Alpermann T, Wulfert M, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013;27:1826–1831.
- Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012;120:3173–3186.
- Visconte V, Mahfouz RZ, Tabarroki A, et al. Biological rationale for the favorable clinical outcomes of patients carrying SF3B1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood (ASH Annual Meeting Abstracts) 2012; 120. Abstract 922.
- Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012;26:542–545.
- Visconte V, Tabarroki A, Zhang L, et al. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk myelodysplastic syndromes with ring sideroblasts. J Hematol Oncol 2014;7:89.
- Zoi K, Cross NC. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable. Int J Hematol 2015;101:229–242. doi: 10.1007/s12185-014-1670-3
- Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391–2405.
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379–2390.
- Broseus J, Lippert E, Harutyunyan AS, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2014;28:1374–1376.
- Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009;114:3538–3545.
- Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012;97: 1036–1041.
- Jeromin S, Haferlach T, Grossmann V, et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica 2013;98:e15–17.